Multiple myeloma
BCMA and GPRC5D CAR-T cells and bispecifics, and what is left after triple-class exposure.
Registry changes (new trials, status, phase, endpoint and readout-date changes, results) come from the OncoSignal store, last verified against ClinicalTrials.gov 2026-11-11 08:26 UTC.
- New trialNew Ph1 trial: NCT07927842
Liping Dou. BCMA/GPRC5D Dual-Target CAR-T Cell Immunotherapy for Relapsed/Refractory Multiple Myeloma
- Results postedResults posted: DREAMM 9 (NCT04091126)
Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma
- PaperAn Open-label, Multicenter, Phase 2 Study to Assess the Safety and Efficacy of Burixafor (GPC-100) in Combination with Propranolol and G-CSF for the Mobilization of Hematopoietic Progenitor Cells in Multiple Myeloma Patients.
Aljawai YM, Shah G, Jeong AR et al. Transplantation and cellular therapy.
- New trialNew Ph1/Ph2 trial: NCT07911748
Beijing Mabworks Biotech Co., Ltd.. A Study of MBS314 for Injection in Participants With Relapsed/Refractory Multiple Myeloma.
- Phase advanceCM336 advances to Ph3 (indication level)
Keymed Biosciences Co.Ltd posted NCT07910903: Study of CM336+CM313 Combination Therapy in Patients With Relapsed or Refractory Multiple Myeloma
- New trialNew Ph3 trial: NCT07910903
Keymed Biosciences Co.Ltd. Study of CM336+CM313 Combination Therapy in Patients With Relapsed or Refractory Multiple Myeloma
- Results postedResults posted: NCT02542657
Ixazomib With Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients With Multiple Myeloma
- Results postedResults posted: NCT05497804
Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial
- PaperDenosumab in multiple myeloma patients with severe renal impairment: a multicenter phase 2 study.
O'Donnell EK, Nadeem O, Laubach JP et al. Blood cancer journal.
- PaperTeclistamab Plus Daratumumab Versus Standard Daratumumab-Based Proteasome Inhibitor Combinations for Relapsed/Refractory Multiple Myeloma: An Inverse Probability of Treatment Weighting Analysis.
Anderson LD Jr, Nair S, Keng MJ et al. Advances in therapy.
- Readout dueReadout due: NCT04680468 reached primary completion
University of Pennsylvania. Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma
- PaperPhase 2 Trial of (89)Zr-Deferoxamine-Daratumumab for CD38-targeted Immuno-PET/CT Detection of Multiple Myeloma.
Ulaner GA, Kuker RA, Diamond B et al. Radiology.
- Readout dueReadout due: NCT04973605 reached primary completion
BeOne Medicines. A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- Readout dueReadout due: UltraFrailMM reached primary completion
University of Utah. Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma
- New trialNew Ph3 trial: iMMagine-6 (NCT07903506)
Kite, A Gilead Company. To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma
- New trialNew Ph2 trial: BEYOND-MM 002 (NCT07903636)
Institute of Hematology & Blood Diseases Hospital, China. QLS4131 for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease
- New trialNew Ph3 trial: TRIlogy-6 (NCT07903272)
Janssen Research & Development, LLC. A Trial Comparing Ramantamig and Daratumumab (Ramantamig-D) Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible
- New trialNew Ph2 trial: GEM-MeziDEL (NCT07901868)
PETHEMA Foundation. Elranatamab With Mezigdomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
- New trialNew Ph2 trial: CAR-T 002 (NCT07895017)
University of Virginia. Time-limited Treatment With Avatrombopag Pre- and Post-CAR T-cell Therapy to Prevent Post-CAR T-cell Cytopenias
- New trialNew Ph2 trial: NCT07891923
Tata Memorial Centre. Less Doses of Daratumumab Are Adequate to Achieve Response in Newly Diagnosed Multiple Myeloma
- New trialNew Ph2/Ph3 trial: NCT07887984
Alliance for Clinical Trials in Oncology. Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple Myeloma
- New trialNew Ph3 trial: iMMagine-4 (NCT07887672)
Kite, A Gilead Company. A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed Multiple Myeloma
- Readout dueReadout due: NCT06049290 reached primary completion
Nanjing Leads Biolabs Co.,Ltd. A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
- PaperChallenges of Conducting a Feasibility Pilot Randomized Controlled Trial During COVID-19 Restrictions: Rivaroxaban Versus Acetyl Salicylic Acid in Patients with Multiple Myeloma on Lenalidomide-Based Therapy (RithMM).
Strelau M, Gal GL, McCurdy A et al. Current oncology (Toronto, Ont.).
- PaperFinal analysis results from DREAMM-3, a phase 3 study of belantamab mafodotin versus pomalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma.
Dimopoulos MA, Hungria V, Meng H et al. Blood cancer journal.
- New trialNew Ph1 trial: NCT07874334
Hadassah Medical Organization. Phase 1a/b Study of GPRC5D CART Therapy in Relapsed/Refractory Multiple Myeloma and Light-chain Amyloidosis
- New trialNew Ph1 trial: (MICRO-CART) (NCT07871747)
University of Chicago. Microbiome Intervention for CAR-T Optimization and Response (MICRO-CART)
- PaperRenal rescue in myeloma: How deep does the hematologic response need to be?
Bachmann F, Knop S. Med (New York, N.Y.).
- PaperBeyond the binding site: PROTAC-mediated protein degradation assists the therapeutic paradigm of hematological malignancies.
Fatahichegeni M, Ansarian MA, Wang Y et al. Leukemia research.
- PaperT-cell-redirecting therapies in early relapsed multiple myeloma: a systematic review and network meta-analysis.
Merz M, Souto Filho JT, Voorhees PM et al. Journal of hematology & oncology.
- PaperBCMA-Targeted Immunotherapy in Early Relapsed/Refractory Multiple Myeloma: Mechanisms, Clinical Evidence, and Practical Management.
Martino M, Bilardi E, Pitea M et al. European journal of haematology.
- PaperMK-4002, a B-cell maturation antigen-targeting T-cell engager, in relapsed or refractory multiple myeloma: a first-in-human, open-label, phase 1 study.
Madan S, Costello C, Lipe B et al. The Lancet. Haematology.
- PaperLong-term outcomes of modified-intensity lenalidomide, bortezomib and dexamethasone (RVD-lite) in transplant-ineligible multiple myeloma: final report of a phase II trial.
Gustine JN, O'Donnell EK, Laubach JP et al. Clinical cancer research : an official journal of the American Association for Cancer Research.
- PaperPlerixafor and G-CSF Versus Placebo and G-CSF in Moderately Mobilizing Patients With Multiple Myeloma to Optimize Hematopoietic Stem Cell Collection Results (OPTIMIZE).
Nina W, Martin S, Andreas T et al. Journal of clinical apheresis.
- Readout dueReadout due: NCT06083922 reached primary completion
Memorial Sloan Kettering Cancer Center. A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
- Readout dueReadout due: NCT05632380 reached primary completion
Institute of Hematology & Blood Diseases Hospital, China. ASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM)
- Readout dueReadout due: SUCCESSOR-2 reached primary completion
Bristol-Myers Squibb. A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
- PaperIberdomide plus daratumumab and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (EXCALIBER-RRMM): an open-label, randomised, controlled, phase 3 trial.
Lonial S, Dimopoulos MA, Gavriatopoulou M et al. The Lancet. Oncology.
- Readout dueReadout due: NCT05392946 reached primary completion
Mayo Clinic. Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study
- Readout dueReadout due: NCT06514508 reached primary completion
Guangzhou Gloria Biosciences Co., Ltd.. Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients
- PaperPatient-reported Outcomes and Healthcare Provider Perspectives on Subcutaneous Isatuximab Delivery via On-body Injector Versus Manual Injection: Results From the Phase 2 IZALCO Study in Relapsed/Refractory Multiple Myeloma.
Parmar G, Capra M, Hungria V et al. Clinical lymphoma, myeloma & leukemia.
- Readout dueReadout due: NCT04933539 reached primary completion
National Cancer Institute (NCI). Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma
- Readout dueReadout due: EASE reached primary completion
AHS Cancer Control Alberta. A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment
- Readout dueReadout due: NCT05900882 reached primary completion
The First Affiliated Hospital with Nanjing Medical University. SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease
- Readout dueReadout due: NCT06152575 reached primary completion
Pfizer. MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Readout dueReadout due: IFM2017_03 reached primary completion
University Hospital, Lille. Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy
- Readout dueReadout due: EMAT reached primary completion
Medical College of Wisconsin. Elimination of Minimal Residual Disease After Transplant
- Readout dueReadout due: QUINTESSENTIAL reached primary completion
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company. Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Phase advanceCyclophosphamide advances to Ph3 in 1L (segment level)
AstraZeneca posted DURGA-6: A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
- Phase advanceFludarabine advances to Ph3 in 1L (segment level)
AstraZeneca posted DURGA-6: A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
- Readout dueReadout due: NCT04876248 reached primary completion
Roswell Park Cancer Institute. Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant
A phase advance is an asset's first trial at a higher phase than any earlier trial of the same asset in this indication. Readout due means the registry's primary completion date has passed; it is not a disclosure.